Levetiracetam (LEV) is one of the most commonly prescribed antiseizure medications (ASM) worldwide for several epilepsy syndromes and diverse clinical scenarios [1,2]. This may be related to this medication’s favorable pharmacokinetic and tolerability profiles – especially if compared with first-generation ASMs such as valproate (VPA), carbamazepine (CBZ), and phenytoin (PHE) [3,4]. It may be reasonable to consider that these advantages inherent to LEV may have led to its excessive use in clinical practice [5].
26
MAR
MAR
0